scholarly article | Q13442814 |
P356 | DOI | 10.1111/1756-185X.13035 |
P8608 | Fatcat ID | release_fp2kwozh3rf2jfwfgt23cn6bdi |
P698 | PubMed publication ID | 28337853 |
P50 | author | Claire Owen | Q85280727 |
P2093 | author name string | Wendy Stevens | |
Gene-Siew Ngian | |||
Mandana Nikpour | |||
Susanna Proudman | |||
Catherine Hill | |||
Joanne Sahhar | |||
Janet Roddy | |||
Peter Youssef | |||
Anton Rajadurai | |||
Daniel Boulos | |||
Kathleen Elford | |||
P2860 | cites work | Cellular and molecular mechanisms of fibrosis | Q24648892 |
The use of mycophenolate mofetil in transplant recipients | Q33957200 | ||
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative | Q34375158 | ||
The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. | Q34457205 | ||
Cyclophosphamide versus placebo in scleroderma lung disease. | Q34540647 | ||
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-ph | Q35878705 | ||
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis | Q36171822 | ||
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. | Q36913821 | ||
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease | Q36932914 | ||
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis | Q37282448 | ||
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials | Q37301159 | ||
Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. | Q37310075 | ||
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). | Q37369608 | ||
Evidence-based management of rapidly progressing systemic sclerosis | Q37763779 | ||
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial | Q41671784 | ||
Improvement in skin thickening in systemic sclerosis associated with improved survival | Q43837375 | ||
Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. | Q44934375 | ||
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis | Q45889664 | ||
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database | Q46274957 | ||
P433 | issue | 4 | |
P921 | main subject | diffuse scleroderma | Q18554846 |
P304 | page(s) | 481-488 | |
P577 | publication date | 2017-03-24 | |
P1433 | published in | International Journal of Rheumatic Diseases | Q15764244 |
P1476 | title | Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease | |
P478 | volume | 20 |
Q91951497 | Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort | cites work | P2860 |
Search more.